Presentation: Mosaicism: Factors in Determination to Implant

Joe Leigh Simpson, MD, FACOG, FACMG, FRCOG
Professor, Obstetrics & Gynecology
Professor, Human and Molecular Genetics
Florida International University
Miami, FL


Learning Objectives

After viewing this presentation, the participant should be able to:
  • Explain the current laboratory methodology for determining whether an embryo is aneuploid, euploid, or mosaic
  • Evaluate the methodology for determining the predictive value of full-term pregnancy after transferring euploid or aneuploid embryos
  • State the likelihood of pregnancy after transferring a single PGT-A euploid embryo in three consecutive cycles until pregnancy is achieved
  • Defend the strategy for transferring a mosaic embryo when no euploid embryo exists in a cohort


 top 
 

Target Audience

This activity is intended to educate nurses and nurse practitioners specializing in reproductive medicine and assisted reproductive technologies.

 top 


Requirements for Successful Completion

To successfully complete this activity for CE credit, the learner will:
1. Take the pretest
2. Review the content in the presentation
3. Complete the posttest with a score of at least 3 correct answers
4. Fill out a brief evaluation


Upon completion of the requirements 1 – 4, a CE certificate will be available for download.


Release & Expiration Dates
May 15, 2025 to October 31, 2025


 top 


Disclosure Information and Off-Label Uses
It is the policy of Letters & Sciences to ensure balance, independence, and scientific rigor in all educational activities/programs. Those who may have the opportunity to influence content of this CNE program (e.g., planners, faculty, authors, reviewers, and others) must disclose all relevant, significant financial relationships with ineligible companies so that the providers may identify and resolve any conflicts of interest prior to the program. Any relevant financial relationships have been mitigated. No relevant financial relationships were identified for any of the individuals with the ability to control content of the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of product(s), device(s) or clinical strategies to the participants at the time of the presentations.

Off-label: The audience is advised that one or more sections in this continuing education activity may contain references to devices and/or protocols or clinical strategies that are unlabeled, investigational, or unapproved by the FDA. Healthcare professionals should note that the use of information presented that is outside of current approved labeling is considered experimental and are advised to consult current prescribing information. The faculty is required to disclose during the presentation any unlabeled, investigational, and/or unapproved uses or therapies that are to be discussed.


Pietro E. Bortoletto, MD, MSc
  • Has received consulting fees from: Gameto Inc, IMMA Health Inc, Rejoni Inc
  • Has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in presentation/materials

Carrie E. Bedient, MD, FACOG
  • Has no conflicts of interest to report
  • Has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in presentation/materials

Leah A. Kaye, MD, MS, FACOG
  • Has no conflicts of interest to report
  • Will be discussing IVF protocols including off-label use of estradiol and progesterone, as well as brief review of nutriceuticals/supplements

Sigal Klipstein, MD, FACOG
  • Is an employee/owner at InVia Fertility Specialists
  • Has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in presentation/materials

Joe Leigh Simpson, MD, FACOG, FACMG, FRCOG
  • Is an employee of Reproductive Genetic Innovations
  • Has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in presentation/materials

Executive Committee, CNE Committee, Planning Committee, Curriculum Committee Members
Letters & Sciences, the content managers/members of the Planning, Executive and Curriculum Committees, report no relationships with ineligible companies.

External Review
In accordance with the policies of Letters & Sciences, and in compliance with the standards of ANCC to identify and resolve any potential conflicts of interest, to assure fair balance, independence and objectivity, and to instill scientific rigor in all accredited activities, all presentations with any potential for conflicts of interest, have been reviewed by external reviewers. The external reviewers, who have no potential conflicts of interest, have determined that no bias exists in these presentations. The external reviewers are:

Shannon L. DeVita, MSN, RN, CNL, DNP
Nurse Practionier
San Diego, California

Michele Nichols, PharmD
Pharmacy Consultant
Private Practice
Raritan, New Jersey
 top 

Accreditation Statements

Continuing Nursing Education with Distinction & Credit Designation Letters & Sciences is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Each presentation has been designated for 0.5 contact hours.

Nonendorsement of Products
The learner is advised that the educational content contained herein was developed by and reflects the opinions of the presenters and faculty, and does not necessarily reflect the opinions or recommendations of the educational provider or the commercial supporters. Accredited status does not imply endorsement by Letters & Sciences or the American Nurses Credentialing Center’s Commission on Accreditation of any commercial product discussed/displayed in conjunction with the educational activity.

 top 


Commercial Support

This program is supported by educational grants from
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany

Ferring Pharmaceuticals, Inc.

Organon LLC


 top 

 

Each CNE activity on this website is eligible for individual credit.